Introduction
Topotecan is a semisynthetic water-soluble inhibitor of topoisomerase I, and acts in the S-phase of the cell cycle. [1] [2] [3] [4] [5] The unique, cell-cycle-specific effect of topotecan suggests that its antitumor activity may be schedule dependent. Accordingly, results in murine xenograft models of human tumors demonstrate peak activity when the drug is given as a protracted infusion. 3 Using similar schedules, excellent antitumor activity is observed in L1210 leukemia, an aggressive murine leukemia, 6 and xenografts of human poor risk acute lymphoblastic leukemia (ALL). 7 Furthermore, recent clinical trials in adults [8] [9] [10] [11] [12] [13] and children 14 demonstrate that continuous infusion topotecan has antileukemia activity.
Preclinical data suggest that the inhibition of topoisomerase I by topotecan will render the cell more susceptible to DNAdamaging agents. 15 The combination of topotecan, plus either cyclophosphamide, 16 idarubicin, 17 etoposide, 18 cisplatin, 19 or cytarabine 9, 11, 16, 18 exhibits antitumor activity in adult patients with leukemia 9, 11, [16] [17] [18] and solid tumors. 19 In hematologic malignancies, thiotepa is an active antileukemic agent that is successfully used in the cytoreduction regimens preceding allogeneic stem cell transplantion (SCT). 20, 21 Additionally, the combination of thiotepa, topotecan, and carboplatin followed by autologous SCT offers a favorable antitumor effect for pediatric solid tumors. 22 Vinorelbine is a semisynthetic Vinca rosea alkaloid. 23, 24 Early in vitro data suggest that vinorelbine may have a role in the treatment the acute leukemias, although it appears to be less active in acute myeloblastic leukemia (AML) when compared to acute lymphoblastic leukemia (ALL). 23, 25, 26 In adult solid tumors, vinorelbine has been used successfully in combination with both gemcitabine and topotecan, 27 but there are no clinical data to define its role in the treatment of leukemias.
Gemcitabine is a novel deoxycytidine analog with activity in hematogenous malignancies. The structure and metabolism of gemcitabine resemble that of cytarabine. 28, 29 However, after phosphorylation, gemcitabine achieves higher relative concentrations, and is retained longer than cytarabine. [30] [31] In vitro cytotoxicity data suggest that gemcitabine has significant activity in acute leukemias. [32] [33] [34] Furthermore, in clinical studies, either alone, [35] [36] [37] [38] or in combination with other agents, 39, 40 gemcitabine has activity against human leukemias.
Glucocorticoids are a mainstay in the treatment of pediatric lymphoid and myeloid leukemias. Dexamethasone may be preferable to prednisone due to enhanced penetration into the cerebral spinal fluid. 41 Many hypothesize that saturation of the glucocorticoid receptor over extended periods of time with high doses of corticosteroids will optimize the antileukemic effect of these agents. Results of a recent trial at the Dana-Farber Cancer Institute support this hypothesis. They observed enhanced bone marrow and peripheral blood blast response to 18 and 150 mg/ m 2 /day dexamethasone when compared to the standard 6 mg/ m 2 /day. 42 We report results of an institutional phase 2 nonrandomized single-arm reinduction protocol, incorporating a combination of topotecan, vinorelbine, thiotepa, gemcitabine, and high-dose dexamethasone, for patients with multiple relapsed or refractory acute leukemias. While the chemotherapeutic agents employed all share the dose-limiting toxicity of myelosuppression, they differ in mechanism of action and metabolism. Furthermore, these are agents not commonly used in current leukemia protocols, and they therefore offer potentially novel mechanisms of action, either alone or in combination, against otherwise heavily pretreated leukemia cells. The 'TVTG' (topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine) protocol is designed to induce disease remission that is of sufficient duration to identify a matched unrelated stem cell donor, and to permit hematopoietic stem cell transplantation in a recipient free of infections and vital organ dysfunction.
Patients and methods
Patients with acute leukemias, who had disease recurrence despite exhausting all conventional therapeutic options, and/or were refractory to conventional therapeutic agents, were eligible for treatment. Between January 1999 and June 2002, 28 patients were treated with a combination of topotecan, vinorelbine, thiotepa, and dexamethasone, with or without gemcitabine according to the Memorial Sloan-Kettering Cancer Center TVTG protocol. All patients had relapsed and/or refractory leukemia, and no patient had therapeutic options of greater curative potential. The diagnosis of ALL or AML was made according to the FAB classification. Confirmation of immunophenotype was available prior to treatment. All patients had a normal serum creatinine, liver transaminases less than five times normal, and a total serum bilirubin less than 1.5 times normal.
According to institutional guidelines, written informed consent was obtained from all patients or their guardians before the initiation of therapy. Institutional Review Board approval was obtained for the analysis of the results.
The specific schedule and dosages of the prescribed chemotherapy is shown in Table 1 . Gemcitabine was infused on day 7 if the following criteria were met: there were greater than 25% leukemic blasts in the day 7 bone marrow or a persistence of circulating blasts in the peripheral blood; and liver transaminases were less than five times normal, with a bilirubin less than 1.5 times normal. Starting on day 7, administration of daily subcutaneous granulocyte colonystimulating factor was initiated and continued until leukocyte recovery. Additional courses of TVTG were offered to those patients with a significant response to the first cycle, and only when the absolute neutrophil count (ANC) exceeded 1000/ml and the platelet count exceeded 75,000/ml (Table 1 ). All patients received either intrathecal methotrexate or cytarabine within 2 weeks of the start of each cycle of TVTG. Subsequent intrathecal chemotherapy was administered at the discretion of the investigator. One patient (patient 21) received intrathecal methotrexate, cytarabine, and thiotepa on days 7, 14, and 21.
A complete response (CR) was defined as no measurable extramedullary disease, and less than 5% blasts in the bone marrow (M1 marrow) in a patient with an ANC greater than 500/ ml, and platelet count greater than 75 000/ml. Patients with a partial response (PR) had 5-25% bone marrow blasts, with an ANC greater than 500/ml, and platelet count greater than 75 000/ ml. It is not uncommon for heavily pretreated patients, especially those with extensive bone marrow infiltration, to have a significant response to therapy but have a delayed recovery of platelet production. Therefore, patients who had an ANC greater than 500/ml, a platelet count less than 75 000/ml, and 5-25% leukemic blasts in the bone marrow were defined as having a PR except platelets (PR-P). Patients who did not meet the above response criteria were defined as unresponsive (n ¼ 15) and were not offered additional courses of TVTG. Toxicities were graded according to the National Cancer Institute common toxicity criteria, version II.
Results
Among the 28 patients enrolled (Table 2) , 19 were male and nine female. The mean age at the initial leukemia diagnosis was 8.1 years (range 3 months-21 years), and the mean age at enrollment was 10.8 years (1-24 years). A total of 14 patients (50%) had Pre-B-cell ALL, three (11%) T-cell ALL, two (7%) biphenotypic leukemia, and nine (32%) AML. Three of the nine cases of AML were secondary to treatment for a previous malignancy (t-AML). A total of 12 patients (43%) had disease refractory to either first remission induction (n ¼ 3) or refractory to remission reinduction after the first (n ¼ 6) or subsequent relapse (n ¼ 3). The remaining 16 patients (57%) had a median of two relapses (range 1-9) per patient, including five patients who relapsed after myeloablative therapy and subsequent allogeneic SCT (patients 4, 6, 10, 14, and 19). There were six patients (21%) who received TVTG as the primary remission reinduction therapy following a first relapse: patient 3 relapsed while on a high-risk ALL protocol, patient 16 had relapsed AML after only 6 weeks of remission, patients 18 and 19 experienced an early relapse after primary refractory disease (refers to disease that was refractory to standard initial remission induction therapy, but ultimately these patients did achieve a first remission with additional therapy), patient 22 had relapsed t-AML, and patient 24 relapsed during consolidation therapy for AML.
In all, 10 of the 28 patients (36%) achieved a CR, one patient (4%) a PR, two (7%) a PR-P (Table 3) , and 15 (53%) had no response following the first cycle of TVTG. A total of 20 patients (71%) had either an M3 marrow on day 7, or a persistence of circulating blasts, and 15 subsequently received gemcitabine. Three of these 15 patients achieved a CR (20%), one a PR (7%), and one a PR-P (7%) after gemcitabine. Reasons to not give gemcitabine in the remaining five patients included: hepatotoxicity (n ¼ 2), and a decision by the medical providers and family that additional therapy would be futile due to rapid progression of disease (n ¼ 3).
Four of the 14 patients (29%) with pre-B-ALL had a CR and one a PR. Two of the three patients with T-cell leukemias had a CR. Four of the nine patients (44%) with AML (including one with t-AML) had a CR, and one a PR-P. One of the two patients with biphenotypic leukemia had a PR-P (Table 3 ). Eight of the 13 patients with a response received more than one cycle of TVTG (mean 3.6 cycles/patient, range 1-5 cycles). Day 21 vinorelbine is given only if the ANC is greater that 500/ml. c Administered if there are greater than 25% leukemic blasts in the bone marrow or a persistence of circulating blasts in the peripheral blood, and if liver transaminases are less than five times normal, with a bilirubin less than 1.5 times normal.
Re
Eight of the 10 patients who achieved a CR, and two of the three patients with a PR underwent an allogeneic hematopoietic SCT after TVTG. The median time from achieving a CR to transplant (n ¼ 7) was 3.9 months (range 1.5-10.9 months). Four patients (patients 1, 2, 12, and 21) had a CR after TVTG, underwent an allogeneic SCT, and are alive and disease free 8, 19, 30, and 49 months from the start of TVTG, respectively. Patient 12 relapsed after the second cycle of TVTG. He again achieved a remission with idarubicin and cytarabine, and is currently alive and well after a mismatched SCT. Of the t-AML, therapy related, or secondary AML; SCT, stem cell transplant; CR, complete response; PR, partial response; PR-P, partial response except platelets; DOD, died of disease recurrence, VOD, veno-occlusive disease. The patient relapsed after the second cycle of TVTG. The patient subsequently achieved remission after therapy with another protocol and was able to undergo an SCT. Patient received intrathecal therapy with methotrexate, cytarabine, thiotepa, and hydrocortisone concomitantly with TVTG.
Re-induction therapy for refractory leukemia EA Kolb and PG Steinherz remaining six patients who were transplanted, two died with relapsed disease, one viral pneumonitis, one veno-occlusive disease, one disseminated aspergillus, and one of complications associated with graft rejection (Table 3 ). All transplant-related morbidities were within the range of that which is normally expected in a heavily pretreated cohort of patients, and none could be directly correlated with the prior administration of TVTG. Three patients were not transplanted after a response to TVTG (patients 15, 22, and 24). Patient 24 had hematopoietic recovery and confirmation of a CR, but the patient died of complications of sepsis and ARDS that occurred during reinduction therapy. This is the only TVTG-associated morbidity or mortality that prevented SCT. After an initial PR-P on TVTG, patient 15 opted to go off protocol and receive consolidation therapy with fludarabine and cytarabine. No stem cell donor was identified, and the patient died of relapsed disease 4.5 months from the start of TVTG. Patient 22 refused additional chemotherapy after a documented CR. This patient ultimately relapsed and died of progressive disease.
The 13 patients who responded to therapy were evaluated for hematopoietic recovery following TVTG. The median time to achieve an ANC of 500/ml was 27 days (range 6-40 days), and median time to achieve a platelet count of 75 000/ml (n ¼ 11) was 30 days (range 0-48 days). The addition of gemcitabine delayed the recovery of both the ANC and the platelet count (Table 4 ). Transient grade 1 or 2 hepatic toxicity is documented in 10 patients. Eight of these 10 patients received gemcitabine. Three patients died within 1 month of starting therapy with TVTG. All three patients had progressive disease on day 7, and ultimately succumbed to disease and/or sepsis. One patient, as mentioned above, developed sepsis and ARDS during cycle 1 of chemotherapy of TVTG. This patient subsequently died 6 weeks after initiation of TVTG, and was in remission at the time.
Discussion
Patients with multiply relapsed or refractory leukemia have a dismal prognosis. Agents available for salvage therapy are limited by: (1) the development of multidrug resistance in the leukemia cells; and (2) the capacity for these heavily pretreated patients to tolerate the side effects of additional high-dose therapy. We present the results of 28 patients treated with a protocol containing topotecan, vinorelbine, thiotepa, gemcitabine, and dexamethasone. A total of 13 of these patients (47%), with multiply relapsed or refractory leukemia, achieved either a CR (10 patients) or a PR (three patients) after one cycle of TVTG. Additionally, 10 of the 13 patients subsequently underwent allogeneic SCT, and four of these are currently alive and diseasefree. It is interesting to note that remission reinduction with TVTG was possible regardless of immunophenotype of the leukemia cells (Table 3) .
Recent clinical trials of topotecan as a single agent demonstrate that the drug has activity in relapsed leukemias. [8] [9] [10] 13, 14 The maximum tolerated dose of topotecan in a heavily pretreated cohort of pediatric patients with refractory leukemia is reportedly 2.4 mg/m 2 /day for 9 days. 14 However, the dose employed in the multidrug protocols is necessarily lower and some investigators have successfully used topotecan at a dose of 1.25 mg/m 2 /day in combination with other agents. 11, 17 In this report, seven patients (25%) achieved a CR, and one a PR-P when topotecan (1 mg/m 2 /day for 5 days) was used in combination with vinorelbine, thiotepa, and dexamethasone (ie without the addition of gemcitabine).
The role of gemcitabine in this combination of drugs is not clear. In total, 15 patients had M3 marrow disease on day 7, and received gemcitabine. Three subsequently achieved a CR, one a PR and one a PR-P. Among the patients who received gemcitabine, ANC recovery (see Table 3 ) was delayed 9 days (32 days with gemcitabine, n ¼ 5 vs 23 days without gemcitabine, n ¼ 8), and the recovery of the platelet count was delayed 3 days (32 days with gemcitabine, n ¼ 4 and 29 days without, n ¼ 7). However, only patients with refractory or progressive disease received gemcitabine, and accordingly were expected to have delayed or no recovery of hematopoiesis. Eight patients experienced grade 2 hepatic toxicity following gemcitabine infusion as compared to only two who did not receive gemcitabine. Nonetheless, three CRs, one PR and one PR-P among 15 patients with a slow response to reinduction are encouraging. Careful consideration of acute toxicities is necessary prior to the administration of gemcitabine.
The role of reinduction chemotherapy in multiply relapsed or refractory patients is not an attempt at cure. Long-term remission duration is unrealistic. Without an SCT, sooner or later these patients will experience disease recurrence. The goal is to administer therapy that will: (1) achieve a clinical response with as little residual disease as possible; (2) maintain the response long enough to identify a matched-unrelated stem cell donor; and (3) permit the patient to undergo an SCT free of infections and vital organ dysfunction. We were able to achieve this goal in 47% of the patients. Unfortunately, one patient with a CR died of complications resulting from ARDS that occurred during induction. Additionally, two patients, with extensive disease at the time of enrollment, experienced increased LFTs during the first week of induction, and were subsequently unable to potentially benefit from gemcitabine despite an M3 day 7 marrow.
In summary, we report a 47% response rate (36% CR, 11% PR) in patients with multiple relapsed leukemia using a new combination of chemotherapeutic agents. Toxicities primarily include grade 4 neutropenia, which is difficult to assess in the setting of a relapsed leukemia, and transient grade 2 hepatic toxicity. Given the remission reinduction rate in this heavily pretreated cohort of patients, these toxicities are acceptable. Re-induction therapy for refractory leukemia EA Kolb and PG Steinherz
